Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors
Journal of Neuro-Oncology, 05/24/2012
Clinical Article
Segura PP et al. – The findings suggest the First–line temozolomide (TMZ) was well tolerated, and did not adversely affect the quality of life of patients with leptomeningeal metastases (LMD).



